newsfilter
← Latest News
GlobeNewswire·

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical data from Ntrust-1 and